The global PARP Inhibitors for Breast Cancer market size was valued at US$ 2.34 billion in 2024 and is projected to reach US$ 4.12 billion by 2030, at a CAGR of 9.9% during the forecast period 2024-2030.
United States PARP Inhibitors for Breast Cancer market size was valued at US$ 1.18 billion in 2024 and is projected to reach US$ 2.04 billion by 2030, at a CAGR of 9.5% during the forecast period 2024-2030.
Drugs that inhibit poly (ADP-ribose) polymerase enzymes, used in the treatment of BRCA-mutated and other types of breast cancer.
Rapid growth supported by expanding indications beyond BRCA-mutated cancers. Increasing use in earlier treatment lines and combination therapies. Ongoing research into biomarkers for patient selection potentially broadening the eligible patient population.
Report Overview
This report provides a deep insight into the global PARP Inhibitors for Breast Cancer market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global PARP Inhibitors for Breast Cancer Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the PARP Inhibitors for Breast Cancer market in any manner.
Global PARP Inhibitors for Breast Cancer Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- AstraZeneca
- Everest Pharmaceuticals
- Pfizer
Market Segmentation (by Type)
Market Segmentation (by Application)
- Hospital
- Clinic
- Drug Center
- Other
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the PARP Inhibitors for Breast Cancer Market
- Overview of the regional outlook of the PARP Inhibitors for Breast Cancer Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value (USD Billion) data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the
major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of PARP Inhibitors for Breast Cancer
1.2 Key Market Segments
1.2.1 PARP Inhibitors for Breast Cancer Segment by Type
1.2.2 PARP Inhibitors for Breast Cancer Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 PARP Inhibitors for Breast Cancer Market Overview
2.1 Global Market Overview
2.1.1 Global PARP Inhibitors for Breast Cancer Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global PARP Inhibitors for Breast Cancer Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 PARP Inhibitors for Breast Cancer Market Competitive Landscape
3.1 Global PARP Inhibitors for Breast Cancer Sales by Manufacturers (2019-2024)
3.2 Global PARP Inhibitors for Breast Cancer Revenue Market Share by Manufacturers (2019-2024)
3.3 PARP Inhibitors for Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global PARP Inhibitors for Breast Cancer Average Price by Manufacturers (2019-2024)
3.5 Manufacturers PARP Inhibitors for Breast Cancer Sales Sites, Area Served, Product Type
3.6 PARP Inhibitors for Breast Cancer Market Competitive Situation and Trends
3.6.1 PARP Inhibitors for Breast Cancer Market Concentration Rate
3.6.2 Global 5 and 10 Largest PARP Inhibitors for Breast Cancer Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 PARP Inhibitors for Breast Cancer Industry Chain Analysis
4.1 PARP Inhibitors for Breast Cancer Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of PARP Inhibitors for Breast Cancer Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 PARP Inhibitors for Breast Cancer Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global PARP Inhibitors for Breast Cancer Sales Market Share by Type (2019-2024)
6.3 Global PARP Inhibitors for Breast Cancer Market Size Market Share by Type (2019-2024)
6.4 Global PARP Inhibitors for Breast Cancer Price by Type (2019-2024)
7 PARP Inhibitors for Breast Cancer Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global PARP Inhibitors for Breast Cancer Market Sales by Application (2019-2024)
7.3 Global PARP Inhibitors for Breast Cancer Market Size (M USD) by Application (2019-2024)
7.4 Global PARP Inhibitors for Breast Cancer Sales Growth Rate by Application (2019-2024)
8 PARP Inhibitors for Breast Cancer Market Segmentation by Region
8.1 Global PARP Inhibitors for Breast Cancer Sales by Region
8.1.1 Global PARP Inhibitors for Breast Cancer Sales by Region
8.1.2 Global PARP Inhibitors for Breast Cancer Sales Market Share by Region
8.2 North America
8.2.1 North America PARP Inhibitors for Breast Cancer Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe PARP Inhibitors for Breast Cancer Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific PARP Inhibitors for Breast Cancer Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America PARP Inhibitors for Breast Cancer Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa PARP Inhibitors for Breast Cancer Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 AstraZeneca
9.1.1 AstraZeneca PARP Inhibitors for Breast Cancer Basic Information
9.1.2 AstraZeneca PARP Inhibitors for Breast Cancer Product Overview
9.1.3 AstraZeneca PARP Inhibitors for Breast Cancer Product Market Performance
9.1.4 AstraZeneca Business Overview
9.1.5 AstraZeneca PARP Inhibitors for Breast Cancer SWOT Analysis
9.1.6 AstraZeneca Recent Developments
9.2 Everest Pharmaceuticals
9.2.1 Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Basic Information
9.2.2 Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Product Overview
9.2.3 Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Product Market Performance
9.2.4 Everest Pharmaceuticals Business Overview
9.2.5 Everest Pharmaceuticals PARP Inhibitors for Breast Cancer SWOT Analysis
9.2.6 Everest Pharmaceuticals Recent Developments
9.3 Pfizer
9.3.1 Pfizer PARP Inhibitors for Breast Cancer Basic Information
9.3.2 Pfizer PARP Inhibitors for Breast Cancer Product Overview
9.3.3 Pfizer PARP Inhibitors for Breast Cancer Product Market Performance
9.3.4 Pfizer PARP Inhibitors for Breast Cancer SWOT Analysis
9.3.5 Pfizer Business Overview
9.3.6 Pfizer Recent Developments
10 PARP Inhibitors for Breast Cancer Market Forecast by Region
10.1 Global PARP Inhibitors for Breast Cancer Market Size Forecast
10.2 Global PARP Inhibitors for Breast Cancer Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe PARP Inhibitors for Breast Cancer Market Size Forecast by Country
10.2.3 Asia Pacific PARP Inhibitors for Breast Cancer Market Size Forecast by Region
10.2.4 South America PARP Inhibitors for Breast Cancer Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of PARP Inhibitors for Breast Cancer by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global PARP Inhibitors for Breast Cancer Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of PARP Inhibitors for Breast Cancer by Type (2025-2030)
11.1.2 Global PARP Inhibitors for Breast Cancer Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of PARP Inhibitors for Breast Cancer by Type (2025-2030)
11.2 Global PARP Inhibitors for Breast Cancer Market Forecast by Application (2025-2030)
11.2.1 Global PARP Inhibitors for Breast Cancer Sales (K Units) Forecast by Application
11.2.2 Global PARP Inhibitors for Breast Cancer Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. PARP Inhibitors for Breast Cancer Market Size Comparison by Region (M USD)
Table 5. Global PARP Inhibitors for Breast Cancer Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global PARP Inhibitors for Breast Cancer Sales Market Share by Manufacturers (2019-2024)
Table 7. Global PARP Inhibitors for Breast Cancer Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global PARP Inhibitors for Breast Cancer Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PARP Inhibitors for Breast Cancer as of 2022)
Table 10. Global Market PARP Inhibitors for Breast Cancer Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers PARP Inhibitors for Breast Cancer Sales Sites and Area Served
Table 12. Manufacturers PARP Inhibitors for Breast Cancer Product Type
Table 13. Global PARP Inhibitors for Breast Cancer Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of PARP Inhibitors for Breast Cancer
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. PARP Inhibitors for Breast Cancer Market Challenges
Table 22. Global PARP Inhibitors for Breast Cancer Sales by Type (K Units)
Table 23. Global PARP Inhibitors for Breast Cancer Market Size by Type (M USD)
Table 24. Global PARP Inhibitors for Breast Cancer Sales (K Units) by Type (2019-2024)
Table 25. Global PARP Inhibitors for Breast Cancer Sales Market Share by Type (2019-2024)
Table 26. Global PARP Inhibitors for Breast Cancer Market Size (M USD) by Type (2019-2024)
Table 27. Global PARP Inhibitors for Breast Cancer Market Size Share by Type (2019-2024)
Table 28. Global PARP Inhibitors for Breast Cancer Price (USD/Unit) by Type (2019-2024)
Table 29. Global PARP Inhibitors for Breast Cancer Sales (K Units) by Application
Table 30. Global PARP Inhibitors for Breast Cancer Market Size by Application
Table 31. Global PARP Inhibitors for Breast Cancer Sales by Application (2019-2024) & (K Units)
Table 32. Global PARP Inhibitors for Breast Cancer Sales Market Share by Application (2019-2024)
Table 33. Global PARP Inhibitors for Breast Cancer Sales by Application (2019-2024) & (M USD)
Table 34. Global PARP Inhibitors for Breast Cancer Market Share by Application (2019-2024)
Table 35. Global PARP Inhibitors for Breast Cancer Sales Growth Rate by Application (2019-2024)
Table 36. Global PARP Inhibitors for Breast Cancer Sales by Region (2019-2024) & (K Units)
Table 37. Global PARP Inhibitors for Breast Cancer Sales Market Share by Region (2019-2024)
Table 38. North America PARP Inhibitors for Breast Cancer Sales by Country (2019-2024) & (K Units)
Table 39. Europe PARP Inhibitors for Breast Cancer Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific PARP Inhibitors for Breast Cancer Sales by Region (2019-2024) & (K Units)
Table 41. South America PARP Inhibitors for Breast Cancer Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa PARP Inhibitors for Breast Cancer Sales by Region (2019-2024) & (K Units)
Table 43. AstraZeneca PARP Inhibitors for Breast Cancer Basic Information
Table 44. AstraZeneca PARP Inhibitors for Breast Cancer Product Overview
Table 45. AstraZeneca PARP Inhibitors for Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. AstraZeneca Business Overview
Table 47. AstraZeneca PARP Inhibitors for Breast Cancer SWOT Analysis
Table 48. AstraZeneca Recent Developments
Table 49. Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Basic Information
Table 50. Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Product Overview
Table 51. Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Everest Pharmaceuticals Business Overview
Table 53. Everest Pharmaceuticals PARP Inhibitors for Breast Cancer SWOT Analysis
Table 54. Everest Pharmaceuticals Recent Developments
Table 55. Pfizer PARP Inhibitors for Breast Cancer Basic Information
Table 56. Pfizer PARP Inhibitors for Breast Cancer Product Overview
Table 57. Pfizer PARP Inhibitors for Breast Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Pfizer PARP Inhibitors for Breast Cancer SWOT Analysis
Table 59. Pfizer Business Overview
Table 60. Pfizer Recent Developments
Table 61. Global PARP Inhibitors for Breast Cancer Sales Forecast by Region (2025-2030) & (K Units)
Table 62. Global PARP Inhibitors for Breast Cancer Market Size Forecast by Region (2025-2030) & (M USD)
Table 63. North America PARP Inhibitors for Breast Cancer Sales Forecast by Country (2025-2030) & (K Units)
Table 64. North America PARP Inhibitors for Breast Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 65. Europe PARP Inhibitors for Breast Cancer Sales Forecast by Country (2025-2030) & (K Units)
Table 66. Europe PARP Inhibitors for Breast Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 67. Asia Pacific PARP Inhibitors for Breast Cancer Sales Forecast by Region (2025-2030) & (K Units)
Table 68. Asia Pacific PARP Inhibitors for Breast Cancer Market Size Forecast by Region (2025-2030) & (M USD)
Table 69. South America PARP Inhibitors for Breast Cancer Sales Forecast by Country (2025-2030) & (K Units)
Table 70. South America PARP Inhibitors for Breast Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 71. Middle East and Africa PARP Inhibitors for Breast Cancer Consumption Forecast by Country (2025-2030) & (Units)
Table 72. Middle East and Africa PARP Inhibitors for Breast Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 73. Global PARP Inhibitors for Breast Cancer Sales Forecast by Type (2025-2030) & (K Units)
Table 74. Global PARP Inhibitors for Breast Cancer Market Size Forecast by Type (2025-2030) & (M USD)
Table 75. Global PARP Inhibitors for Breast Cancer Price Forecast by Type (2025-2030) & (USD/Unit)
Table 76. Global PARP Inhibitors for Breast Cancer Sales (K Units) Forecast by Application (2025-2030)
Table 77. Global PARP Inhibitors for Breast Cancer Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of PARP Inhibitors for Breast Cancer
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global PARP Inhibitors for Breast Cancer Market Size (M USD), 2019-2030
Figure 5. Global PARP Inhibitors for Breast Cancer Market Size (M USD) (2019-2030)
Figure 6. Global PARP Inhibitors for Breast Cancer Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. PARP Inhibitors for Breast Cancer Market Size by Country (M USD)
Figure 11. PARP Inhibitors for Breast Cancer Sales Share by Manufacturers in 2023
Figure 12. Global PARP Inhibitors for Breast Cancer Revenue Share by Manufacturers in 2023
Figure 13. PARP Inhibitors for Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market PARP Inhibitors for Breast Cancer Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by PARP Inhibitors for Breast Cancer Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global PARP Inhibitors for Breast Cancer Market Share by Type
Figure 18. Sales Market Share of PARP Inhibitors for Breast Cancer by Type (2019-2024)
Figure 19. Sales Market Share of PARP Inhibitors for Breast Cancer by Type in 2023
Figure 20. Market Size Share of PARP Inhibitors for Breast Cancer by Type (2019-2024)
Figure 21. Market Size Market Share of PARP Inhibitors for Breast Cancer by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global PARP Inhibitors for Breast Cancer Market Share by Application
Figure 24. Global PARP Inhibitors for Breast Cancer Sales Market Share by Application (2019-2024)
Figure 25. Global PARP Inhibitors for Breast Cancer Sales Market Share by Application in 2023
Figure 26. Global PARP Inhibitors for Breast Cancer Market Share by Application (2019-2024)
Figure 27. Global PARP Inhibitors for Breast Cancer Market Share by Application in 2023
Figure 28. Global PARP Inhibitors for Breast Cancer Sales Growth Rate by Application (2019-2024)
Figure 29. Global PARP Inhibitors for Breast Cancer Sales Market Share by Region (2019-2024)
Figure 30. North America PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America PARP Inhibitors for Breast Cancer Sales Market Share by Country in 2023
Figure 32. U.S. PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada PARP Inhibitors for Breast Cancer Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico PARP Inhibitors for Breast Cancer Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe PARP Inhibitors for Breast Cancer Sales Market Share by Country in 2023
Figure 37. Germany PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific PARP Inhibitors for Breast Cancer Sales and Growth Rate (K Units)
Figure 43. Asia Pacific PARP Inhibitors for Breast Cancer Sales Market Share by Region in 2023
Figure 44. China PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America PARP Inhibitors for Breast Cancer Sales and Growth Rate (K Units)
Figure 50. South America PARP Inhibitors for Breast Cancer Sales Market Share by Country in 2023
Figure 51. Brazil PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa PARP Inhibitors for Breast Cancer Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa PARP Inhibitors for Breast Cancer Sales Market Share by Region in 2023
Figure 56. Saudi Arabia PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa PARP Inhibitors for Breast Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global PARP Inhibitors for Breast Cancer Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global PARP Inhibitors for Breast Cancer Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global PARP Inhibitors for Breast Cancer Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global PARP Inhibitors for Breast Cancer Market Share Forecast by Type (2025-2030)
Figure 65. Global PARP Inhibitors for Breast Cancer Sales Forecast by Application (2025-2030)
Figure 66. Global PARP Inhibitors for Breast Cancer Market Share Forecast by Application (2025-2030)
